文献速递MDS 与骨髓增殖性肿瘤

晚期骨髓增殖性肿瘤伴随染色体异常导致TP53失调

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
PubMed 文献 · Blood Adv · 2018-01-01

该研究在1294例费城染色体阴性骨髓增殖性肿瘤患者中,探讨涉及1、12和17号染色体的异常是否与疾病进展相关。结果显示1q增益见于PV、ET及MPN-BP患者,且伴MDM4转录水平升高;12q异常仅见于MF或MPN-BP患者,17p13缺失患者均表现为MF或MPN-AP/BP。

要点

  • 1q增益不仅见于MPN-BP,也见于PV和ET患者,且最常见于有PV病史及携带JAK2V617F驱动突变者。
  • 12q染色体异常仅见于表现为MF或MPN-BP的患者,未伴随MDM2/MDM4转录水平进一步升高。
  • 所有17p13缺失(导致TP53缺失)患者均表现为MF或MPN-AP/BP。

核心结论

  • 1q增益和17p缺失与TP53通路扰动相关,可能促进MPN疾病进展。

研究设计与样本

  • 在1294例费城染色体阴性骨髓增殖性肿瘤患者中,研究涉及1、12和17号染色体的异常与MPN疾病进展的关联。

主要发现

  • 1q增益见于MPN-BP患者,也见于PV和ET患者,这些患者随进一步随访最终演变为MF和/或MPN-BP。
  • 1q增益最常见于有PV病史的患者及携带JAK2V617F驱动突变的患者,并伴随MDM4转录水平升高。
  • 12q染色体异常仅见于表现为MF或MPN-BP的患者,未伴随MDM2/MDM4转录水平进一步升高。
  • 所有17p13缺失导致TP53缺失的患者均表现为MF或MPN-AP/BP。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and the prefibrotic form of primary myelofibrosis (PMF), frequently progress to more overt forms of MF and a type of acute leukemia termed MPN-accelerated phase/blast phase (MPN-AP/BP). Recent evidence indicates that dysregulation of the tumor suppressor tumor protein p53 (TP53) commonly occurs in the MPNs. The proteins MDM2 and MDM4 alter the cellular levels of TP53. We investigated in 1,294 patients whether abnormalities involving chromosomes 1 and 12, which harbor the genes for MDM4 and MDM2, respectively, and chromosome 17, where the gene for TP53 is located, are associated with MPN disease progression. Gain of 1q occurred not only in individuals with MPN-BP but also in patients with PV and ET, who, with further follow-up, eventually evolve to either MF and/or MPN-BP. These gains of 1q were most prevalent in patients with a history of PV and those who possessed the JAK2V617F driver mutation. The gains of 1q were accompanied by increased transcript levels of MDM4 In contrast, 12q chromosomal abnormalities were exclusively detected in patients who presented with MF or MPN-BP, but were not accompanied by further increases in MDM2/MDM4 transcript levels. Furthermore, all patients with a loss of 17p13, which leads to a deletion of TP53, had either MF or MPN-AP/BP. These findings suggest that gain of 1q, as well as deletions of 17p, are associated with perturbations of the TP53 pathway, which contribute to MPN disease progression.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Marcellino BK, Hoffman R, Tripodi J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018. PMID: 30563882. doi:10.1182/bloodadvances.2018024018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。